Description: Yourgene Health PLC, formerly Premaitha Health PLC, is engaged in molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for pre-natal screening and other clinical applications in the early detection, monitoring and treatment of disease. The Company's product, the IONA test is a non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer a regulated non-invasive prenatal test in-house. The IONA test estimates the risk of a fetus having Down's syndrome or other serious genetic diseases. The risks that fetus may be affected with include Trisomy 21 (Down's syndrome), Trisomy 18 (Edwards' syndrome), Trisomy 13 (Patau's syndrome) and Fetal sex determination optional. The analysis is performed on cell-free placental deoxyribonucleic acid (DNA) from a maternal blood sample, with test results available in three days turnaround time.
Home Page: www.yourgene-health.com
YGEN Technical Analysis
Skelton House
Manchester,
M15 6SH
United Kingdom
Phone:
44 16 1669 8122
Officers
| Name | Title |
|---|---|
| Mr. Lyn Dafydd Rees | CEO & Director |
| Mr. Barry Hextall | CFO, Sec. & Exec. Director |
| Mr. Hayden William Jeffreys | COO & Director |
| Dr. Joanne Mason | Chief Scientific Officer & Director |
| Dr. Chia-Han Chang, Chan Ph.D. | Chief Entrepreneur & Director |
| Ms. Zoe Crookes | Legal Counsel |
| Ms. Joanne Cross | Director of Marketing |
| Ms. Wendy Cox | HR Director |
| Dr. Michael Risley | Chief Devel. Officer |
| Dr. Matthew Forman | Head of Bioinformatics & Software |
Exchange: LSE
Country: UK : United Kingdom
Currency: Pence sterling (p)
| Forward PE: | 77.5194 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4163 |
| Price-to-Sales TTM: | 0.3916 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 253 |